Related Experiment Video
Updated: Sep 2, 2025

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
Published on: June 13, 2019
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics
Ugo Chianese1, Chiara Papulino1, Eugenia Passaro1
1Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Objective:
Aberrant activity of androgen receptor (AR) is the primary cause underlying development and progression of prostate cancer (PCa) and castration-resistant PCa (CRPC). Androgen signaling regulates gene transcription and lipid metabolism, facilitating tumor growth and therapy resistance in early and advanced PCa. Although direct AR signaling inhibitors exist, AR expression and function can also be epigenetically regulated. Specifically, lysine (K)-specific demethylases (KDMs), which are often overexpressed in PCa and CRPC phenotypes, regulate the AR transcriptional program.
Methods:
We investigated LSD1/UTX inhibition, two KDMs, in PCa and CRPC using a multi-omics approach. We first performed a mitochondrial stress test to evaluate respiratory capacity after treatment with MC3324, a dual KDM-inhibitor, and then carried out lipidomic, proteomic, and metabolic analyses. We also investigated mechanical cellular properties with acoustic force spectroscopy.
Results:
MC3324 induced a global increase in H3K4me2 and H3K27me3 accompanied by significant growth arrest and apoptosis in androgen-responsive and -unresponsive PCa systems. LSD1/UTX inhibition downregulated AR at both transcriptional and non-transcriptional level, showing cancer selectivity, indicating its potential use in resistance to androgen deprivation therapy. Since MC3324 impaired metabolic activity, by modifying the protein and lipid content in PCa and CRPC cell lines. Epigenetic inhibition of LSD1/UTX disrupted mitochondrial ATP production and mediated lipid plasticity, which affected the phosphocholine class, an important structural element for the cell membrane in PCa and CRPC associated with changes in physical and mechanical properties of cancer cells.
Conclusions:
Our data suggest a network in which epigenetics, hormone signaling, metabolite availability, lipid content, and mechano-metabolic process are closely related. This network may be able to identify additional hotspots for pharmacological intervention and underscores the key role of KDM-mediated epigenetic modulation in PCa and CRPC.
Insights
Inhibition of lysine-specific demethylases (KDMs) with MC3324 halts prostate cancer (PCa) growth by disrupting AR signaling and altering cell metabolism. This epigenetic approach shows promise for treating castration-resistant prostate cancer (CRPC).
Area of Science:
- Epigenetics and Cancer Biology
- Molecular Oncology
- Metabolic Regulation
Background:
- Aberrant androgen receptor (AR) activity drives prostate cancer (PCa) and castration-resistant PCa (CRPC) progression.
- AR signaling influences gene transcription and lipid metabolism, promoting tumor growth and therapy resistance.
- Epigenetic mechanisms, including lysine-specific demethylases (KDMs), regulate AR expression and function in PCa.
Purpose of the Study:
- To investigate the effects of dual KDM inhibition (LSD1/UTX) using MC3324 on PCa and CRPC.
- To explore the impact of KDM inhibition on AR signaling, cellular metabolism, and mechanical properties.
- To evaluate the potential of KDM-mediated epigenetic modulation as a therapeutic strategy for PCa and CRPC.
Main Methods:
- Utilized a multi-omics approach including lipidomics, proteomics, and metabolic analyses.
- Performed mitochondrial stress tests to assess respiratory capacity.
- Employed acoustic force spectroscopy to investigate cellular mechanical properties.
Main Results:
- MC3324 treatment induced global H3K4me2 and H3K27me3 increases, leading to significant growth arrest and apoptosis in PCa and CRPC cells.
- LSD1/UTX inhibition downregulated AR at both transcriptional and non-transcriptional levels, demonstrating cancer selectivity.
- Impaired metabolic activity, disrupted mitochondrial ATP production, and altered lipid plasticity, particularly affecting the phosphocholine class, were observed.
Conclusions:
- Epigenetic inhibition of KDMs is a viable strategy against PCa and CRPC, targeting AR signaling and metabolic pathways.
- A complex network links epigenetics, hormone signaling, metabolism, and cell mechanics in PCa.
- KDM-mediated epigenetic modulation offers potential for novel pharmacological interventions in prostate cancer treatment.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Inhibition of Cdk Activity
Spreading of Chromatin Modifications
Writers
The writer...
Drugs that Stabilize Microtubules
Abnormal Proliferation

